期刊
OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
卷 82, 期 11, 页码 667-680出版社
AMER OPTOMETRIC ASSN INC
DOI: 10.1016/j.optm.2011.08.008
关键词
Zeaxanthin; Lutein; Carotenoids; Macular pigment; Atrophic age-related macular degeneration
资金
- Captain James A. Lovell Federal Health Care Facility, North Chicago, Illinois
- Department of Veterans Affairs Research Service/CARES (Hines, Illinois)
- Chrysantis, Inc. (West Chicago, Illinois)
- Kowa Optimed, Inc. (Torrance, California and Tokyo, Japan)
- Stereo Optical, Inc. (Chicago, Illinois)
- Rush Ophthalmics, Inc. (Gold Beach, Oregon)
- Pharmanex, Inc. (Provo, Utah)
- ZeaVision, Inc. (Chesterfield, Missouri)
- Heidelberg Instruments, Inc. (Heidelberg, Germany)
- RTVue (Fremont, California)
BACKGROUND: The purpose of this study is to evaluate whether dietary supplementation with the carotenoid zeaxanthin (Zx) raises macula pigment optical density (MPOD) and has unique visual benefits for patients with early atrophic macular degeneration having visual symptoms but lower-risk National Institute of Health/National Eye Institute/Age-Related Eye Disease Study characteristics. METHODS: This was a 1-year, n = 60 (57 men, 3 women), 4-visit, intention-to-treat, prospective, randomized controlled clinical trial of patients (74.9 years, standard deviation [SD] 10) with mild-to-moderate age-related macular degeneration (AMD) randomly assigned to 1 of 2 dietary supplement carotenoid pigment intervention groups: 8 mg Zx (n = 25) and 8 mg Zx plus 9 mg lutein (L) (n = 25) or 9 mg L (Faux Placebo, control group, n = 10). Analysis was by Bartlett's test for equal variance, 3-way repeated factors analysis of variance, independent t test (P < 0.05) for variance and between/within group differences, and post-hoc Scheffe's tests. Estimated foveal heterochromic flicker photometry, 1 degrees macular pigment optical density (MPOD QuantifEye (R)), low- and high-contrast visual acuity, foveal shape discrimination (Retina Foundation of the Southwest), 10 yellow kinetic visual fields (KVF), glare recovery, contrast sensitivity function (CSF), and 6 degrees blue cone ChromaTest (R) color thresholds were obtained serially at 4, 8, and 12 months. RESULTS: Ninety percent of subjects completed >= 2 visits with an initial Age-Related Eye Disease Study report #18 retinopathy score of 1.4(1.0 SD)/4.0 and pill intake compliance of 96% with no adverse effects. There were no intergroup differences in 3 major AMD risk factors: age, smoking, and body mass index as well as disease duration and Visual Function Questionnaire 25 composite score differences. Randomization resulted in equal MPOD variance and MPOD increasing in each of the 3 groups from 0.33 density units (du) (0.17 SD) baseline to 0.51 du (0.18 SD) at 12 m, (P = 0.03), but no between-group differences (Analysis of Variance; P = 0.47). In the Zx group, detailed high-contrast visual acuity improved by 1.5 lines, Retina Foundation of the Southwest shape discrimination sharpened from 0.97 to 0.57 (P = 0.06, 1-tail), and a larger percentage of Zx patients experienced clearing of their KVF central scotomas (P = 0.057). The Faux Placebo L group was superior in terms of low-contrast visual acuity, CSF, and glare recovery, whereas Zx showed a trend toward significance. CONCLUSION: In older male patients with AMD, Zx-induced foveal MPOD elevation mirrored that of L and provided complementary distinct visual benefits by improving foveal cone-based visual parameters, whereas L enhanced those parameters associated with gross detailed rod-based vision, with considerable overlap between the 2 carotenoids. The equally dosed (atypical dietary ratio) Zx plus L group fared worse in terms of raising MPOD, presumably because of duodenal, hepatic-lipoprotein or retinal carotenoid competition. These results make biological sense based on retinal distribution and Zx foveal predominance. Optometry 2011;82:667-680
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据